Next Article in Journal
Novel Therapeutic Method for Unresectable Pancreatic Cancer—The Impact of the Long-Term Research in Therapeutic Effect of High-Intensity Focused Ultrasound (HIFU) Therapy
Previous Article in Journal
Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma
Article

Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario

1
HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada
2
AstraZeneca Canada, Mississauga, ON L4Y 1M4, Canada
3
The Ottawa Hospital General Campus, Ottawa, ON K1H 8L6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(6), 4832-4844; https://doi.org/10.3390/curroncol28060408
Received: 8 October 2021 / Revised: 9 November 2021 / Accepted: 13 November 2021 / Published: 19 November 2021
Information on the real-world experience of Canadians diagnosed with chronic lymphocytic leukemia (CLL) is limited. This study was conducted to report treatment patterns and outcomes of CLL using Ontario administrative data. A retrospective cohort study was conducted in patients diagnosed with CLL between 1 January 2010 and 31 December 2017 identified in the Ontario Cancer Registry (OCR). Data were accessed using the Institute of Clinical Evaluative Sciences (ICES), which collects various population-level health information. In the Ontario Cancer Registry, 2887 CLL patients receiving treatment and diagnosed between 2010–2017 were identified. Fludarabine, cyclophosphamide and rituximab (FCR) chemoimmunotherapy was most frequently used as a first line, but use declined since ibrutinib and obinutuzumab combinations were funded in 2015. In patients treated with frontline FCR, survival at year one was 89% pre-2015 and 96% post-2015; at year four, survival was 73% and 87%, respectively. Survival in patients treated with frontline chlorambucil was 76% pre-2015 and 75% post-2015 in year 1, and 45% and 56% in year 3. Our analysis shows that, as the treatment landscape for CLL has shifted, use of newer and novel agents as a first line or earlier in the relapsed/refractory setting has resulted in improved survival outcomes. View Full-Text
Keywords: CLL; cancer; survival; cost; treatment patterns; Canada CLL; cancer; survival; cost; treatment patterns; Canada
Show Figures

Figure 1

MDPI and ACS Style

Seung, S.J.; Hurry, M.; Hassan, S.; Elnoursi, A.; Scheider, K.A.B.; Wagner, D.; Edwin, J.J.; Aw, A.T.W. Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario. Curr. Oncol. 2021, 28, 4832-4844. https://doi.org/10.3390/curroncol28060408

AMA Style

Seung SJ, Hurry M, Hassan S, Elnoursi A, Scheider KAB, Wagner D, Edwin JJ, Aw ATW. Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario. Current Oncology. 2021; 28(6):4832-4844. https://doi.org/10.3390/curroncol28060408

Chicago/Turabian Style

Seung, Soo J., Manjusha Hurry, Shazia Hassan, Ashlie Elnoursi, Krystin A.B. Scheider, Dennis Wagner, Jonathan J. Edwin, and Andrew T.W. Aw 2021. "Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario" Current Oncology 28, no. 6: 4832-4844. https://doi.org/10.3390/curroncol28060408

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop